Author/Authors :
Larijani, B tehran university of medical sciences tums - Public Health School, Endocrinology and Metabolism Research Center(EMRC), تهران, ايران , Heshmat, R tehran university of medical sciences tums - Public Health School, Endocrinology and Metabolism Research Center (EMRC) - Department of Epidemiology and Biostatistics, تهران, ايران , Bahrami, A tabriz university of medical sciences - Endocrinology Research Center, ايران , Delshad, H Iranians’ Hospital - Internal Diseases Ward, United Arab Emirates , Ranjbar Omrani, G shiraz university of medical sciences - Endocrine Metabolism Research Center, ايران , Mohammad, K tehran university of medical sciences tums - Public Health School - Department of Epidemiology and Biostatistics, تهران, ايران , Heidarpour, R tehran university of medical sciences tums - Public Health School, Endocrinology and Metabolism Research Center (EMRC), تهران, ايران , Mohajeri Tehrani, MR tehran university of medical sciences tums - Public Health School, Endocrinology and Metabolism Research Center (EMRC), تهران, ايران , Kamali, K tehran university of medical sciences tums - Public Health School - Department of Epidemiology and Biostatistics, تهران, ايران , Farhadi, M iran university of medical sciences - ENT - Head Neck Surgery Department and Research Center, ايران , Gharibdoust, F tehran university of medical sciences tums - Rheumatology Research Center, تهران, ايران , Madani, SH Rabe Rashidi Institute - Department of Biotechnology, ايران
Abstract :
Some diabetic foot ulcers, which are notoriously difficult to cure, are one of the most common health problems in diabetic patients .There are several surgical and medical options which already have been introduced for treatment of diabetic foot ulcers, so some patient will require amputation. The purpose of this study was to evaluate the efficacy of intravenous Semelil (ANGIPARSTM), a naive herbal extract to accelerate healing of diabetic foot ulcers. A multi-centric randomized controlled trial was conducted to evaluate intravenous Semelil for healing of diabetic foot ulcers. Sixteen diabetic patients were treated with intravenous Semelil, and nine other patients were treated with placebo as control group. Both groups were otherwise treated by wound debridement and irrigation with normal saline solution, systemic antibiotic therapy and daily wound dressing. Before and after intervention, the foot ulcer surface area was measured, by digital photography, mapping and planimetry. After 4 weeks, the mean foot ulcer surface area decreased from 479.93±379.75 mm² to 198.93±143.75 mm² in the intervention group (p = 0.000) and from 766.22±960.50 mm² to 689.11±846.74 mm² in the control group (p = 0.076). Average wound closure in the treatment group was significantly greater than placebo group (64% vs. 25%, p= 0.015). This herbal extract by intravenous rout in combination with conventional therapy is more effective than conventional therapy by itself probably without side effect. However, further studies are required in the future to confirm these results in larger population.
Keywords :
Diabetes mellitus , Foot ulcer , Treatment , Semelil , ANGIPARS™
